Safety and Tolerability of MA09-hRPE Cells in Patients With Stargardt's Macular Dystrophy(SMD)
NCT01625559
·
clinicaltrials.gov ↗
PHASE1
Phase
COMPLETED
Status
3
Enrollment
INDUSTRY
Sponsor class
Conditions
Stargardt's Macular Dystrophy
Interventions
BIOLOGICAL:
MA09-hRPE
Sponsor
CHABiotech CO., Ltd